Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR mutation testing on plasma and urine samples: A pilot study evaluating the value of liquid biopsy in lung cancer diagnosis and management.

Current problems in cancer - 1 Dec 2021

Satapathy Shraddhanjali, Singh Varsha, Nambirajan Aruna, Malik Prabhat Singh, Tanwar Pranay, Mehta Anurag, Suryavanshi Moushumi, Thulkar Sanjay, Mohan Anant, Jain Deepali

Abstract excerpt

BACKGROUND: Cell free DNA (cfDNA) shed by cancer cells into blood and body fluids is a potential substrate for molecular testing. While plasma is approved for EGFR mutation testing in certain clinical settings, mutation testing on urine is not well explored in lung cancer. In this study, we assess the feasibility and diagnostic accuracy of EGFR mutation analysis on plasma and urine samples. METHODS: Matched...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, erbB-1

Share to Liquid Biopsy

Share to Lung Neoplasms

Share to Pilot Projects

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 33712318
DOI: 10.1016/j.currproblcancer.2021.100722

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR mutation testing on plasma and urine samples: A pilot study evaluating the value of liquid biopsy in lung cancer diagnosis and management.PMID 33712318Read ↗

EGFR detection by liquid biopsy: ripe for clinical usage.Semantic proximity Read ↗

Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancerSemantic proximity Read ↗

Epidermal growth factor receptor mutation testing: From conventional to real-time diagnosis of lung cancer.Semantic proximity Read ↗

Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCRSemantic proximity Read ↗

Evaluation of molecular methods for plasma detection of EGFR mutations in non-small cell lung cancer.Semantic proximity Read ↗

EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCRSemantic proximity Read ↗

Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.Semantic proximity Read ↗

Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.Semantic proximity Read ↗

Complementing Tissue Testing with Plasma mutation Profiling Improves Therapeutic Decision Making for Lung Cancer PatientsSemantic proximity Read ↗

Quantitative analysis of cell-free DNA by droplet digital PCR reveals the presence of EGFR mutations in non-malignant lung pathologies.Semantic proximity Read ↗

Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.Semantic proximity Read ↗

Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.